Clinics in Dermatology
Volume 24, Issue 5 , Pages 438-447 , September 2006

Psoriasis and psoriatic arthritis: clinical features and disease mechanisms

  • Wendy A. Myers, MD

      Affiliations

    • UMDNJ-Robert Wood Johnson Medical School, Psoriasis Center of Excellence, New Brunswick, NJ 08903,USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Alice B. Gottlieb, MD

      Affiliations

    • Department of Dermatology, Tufts University School of Medicine, Tufts-New England Medical Center, Boston, MA 02111, USA
    • ,
  • Philip Mease, MD

      Affiliations

    • Seattle Rheumatology Associates, Rheumatology Clinical Research, Swedish Hospital Medical Center, University of Washington School of Medicine, Seattle, WA 98104, USA

References 

  1. National Psoriasis Foundation [Online]. 2006 March 30 [cited 2006 April 10]; Available from: URL: http://www.psoriasis.org.
  2. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmstead County, Minnesota, USA, 1982-1991. J Rheumatol. 2000;27:1247–1250
  3. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc. 1978;53:511–518
  4. Salonen S. The EUROPSO psoriasis patients study: treatment history and satisfaction reported by 17,900 members of European psoriasis patients associations (poster). In: Spring Symposium of the European Academy of Dermatology and Venereology. Malta. 2003;
  5. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573
  6. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450–456
  7. Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46:867–873
  8. Weinstein GD, Menter MA. An overview of psoriasis. In:  Weinstein GD,  Gottlieb AB editor. Therapy of moderate to severe psoriasis. 2nd ed.. New York (NY): Marcel Dekker Inc; 2003;p. 1–28
  9. Langley RGB, Kreuger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl II):ii18–ii23
  10. Elder JT, Nair RP, Henseler T, et al. The Genetics of Psoriasis 2001: The odyssey continues. Arch Dermatol. 2001;137:1447–1454
  11. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301:555
  12. Khandke L, Krane JF, Ashinoff R, et al. Cyclosporine in psoriasis treatment: inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways. Arch Dermatol. 1991;127:1172–1179
  13. Gottlieb AB. Psoriasis: immunopathology and immunomodulation. Dermatol Clin. 2001;19:649–657
  14. Kreuger G, Ellis CN. Psoriasis—recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53:S94–S100
  15. Galadari I, Sharif MO, Galadari H. Psoriasis: a fresh look. Clin Dermatol. 2005;23:491–502
  16. de Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatol Ther. 2004;17:341–349
  17. Ozawa M, Aiba S. Immunopathogenesis of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:137–144
  18. Chaiman F, Kreuger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol. 2004;16:331–337
  19. Gottlieb AB, Chaiman F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175:2721–2729
  20. Gottlieb AB. Immunobiologicals for psoriasis: using targeted immunotherapies as pathogenic probes in psoriasis. In:  Weinstein GD,  Gottlieb AB editor. Therapy of moderate to severe psoriasis. 2nd ed.. New York: Marcel Dekker; 2003;p. 239–286
  21. Gladman D, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–ii17
  22. Mease PJ, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol. 2005;52:1–19
  23. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778–783
  24. Kruithof E, Baeten D, DeRycke L, et al. Synovial histopathology of psoriatic arthritis, either oligo- or polyarticular, resembles more spondyloarthropathy than rheumatoid arthritis [abstract]. Arthritis Res Ther. 2004;50(Suppl 431):s209
  25. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum. 1999;42:1080–1086
  26. Appel H, Loddenkemper C, Kuhne M, et al. Osteoclastic vasoproliferative lesions and subchondral T cell infiltrates at the bone/cartilage interface in AS patients with hip arthritis. Ann Rheum Dis. 2005;64(Suppl 3):108
  27. Han C, Robinson D, Hackett M, et al. Co-occurrences of selected cardiovascular diseases and risk factors in patients with rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 3):108
  28. Mease P, Menter A. Quality of life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54:685–704
  29. Rahman P, Elder J. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 2):ii37–ii39
  30. Gladman DD, Farewell VT, Pellet F, et al. HLA is a candidate region for psoriatic arthritis: evidence for excessive HLA sharing in sibling pairs. Hum Immunol. 2003;64:887–889
  31. Gladman DD, Anhorn KA, Schachter RK, et al. HLA antigens in psoriatic arthritis. J Rheumatol. 1986;13:586–592
  32. Baeten D, Kruithof E, DeRycke L, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther. 2005;7:R359–R369
  33. Veale D, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;65(Suppl 2):ii26–ii29
  34. Mease P. TNF alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis. 2004;63:755–758
  35. van de Kerkhof PCM, Vissers WHPM. Established treatments of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:145–156
  36. Mease PJ. Psoriatic arthritis/psoriasis. In:  Smolen JS,  Lipsky PE editor. Targeted therapies in rheumatology. London: Martin Dunitz; 2003;p. 525–548
  37. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDS and traditional DMARDs. Ann Rheum Dis. 2005;64(Suppl 2):ii74–ii77
  38. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomized, double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859–864
  39. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum. 2004;50:1939–1950
  40. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2013–2020
  41. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1996;39:2013–2020
  42. Whiting-O'Keefe QE, Fye KH, Ward JR, et al. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711–716
  43. Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4:19–34
  44. daSilva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002;168:4462–4471
  45. Krueger G, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821–833
  46. Lebwohl M, Christophers E, Langley R, et al. Alefacept clinical study group An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719–727
  47. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006;54:1638–1645
  48. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004–2013
  49. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52(3 Pt 1):425–433
  50. Jordan JK. Efalizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother. 2005;39:1476–1482
  51. Papp K, Mease P, Garovoy M, et al. Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo controlled study. In: International Psoriasis Symposium. Toronto. 2004;
  52. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022
  53. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000;356:385–390
  54. Mease P, Kivitz A, Burch F, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272
  55. Mease P. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712–721
  56. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374
  57. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–1236
  58. Antoni C, Kreuger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157
  59. Mease P, Kavanaugh A, Kreuger G, et al. Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from IMPACT 2 trial. [abstract] Arthritis Rheum. 2004;50(Suppl 9):S616
  60. van der Heijde , Kavanaugh A, Beutler A, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic damage in patients with active psoriatic arthritis: results from IMPACT 2 trial. Ann Rheum Dis. 2005;64(9 Suppl 3):109
  61. Ritchlin C, Anandarajaha A, Totterman S, et al. Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis. [abstract] Ann Rheum Dis. 2004;63(Suppl 1):403
  62. Mease P, Gladman D, Ritchlin C. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of ADEPT. Arthritis Rheum. 2005;58:3279–3289

PII: S0738-081X(06)00098-8

doi: 10.1016/j.clindermatol.2006.07.006

Clinics in Dermatology
Volume 24, Issue 5 , Pages 438-447 , September 2006

Article Tools